Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$71.53M

FY 2025 · Annual

Investing Cash Flow

-$72.92M

FY 2025 · Annual

Financing Cash Flow

$322.98M

FY 2025 · Annual

+5983301.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.43M)(46.69M)(36.9M)(37.88M)(149.94M)
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
Deferred Income Tax2.17K0000
Stock-Based Compensation6.09M3.86M3.56M4.77M13.3M
Change in Working Capital(1.17M)(4.66M)(2.56M)1.16M(13.37M)
Accounts Receivables0000(18M)
Inventory00000
Accounts Payables17.68K(1.14M)(102.08K)(538.81K)2.08M
Other Working Capital(1.18M)(3.52M)(2.46M)1.7M2.55M
Other Non-Cash Items749.04K828.51K864.87K814.48K78.4M
Operating Cash Flow(57.49M)(46.46M)(34.88M)(31.1M)(71.53M)
Capital Expenditures(14.94K)(84.19K)(21.39K)(9.97K)(919K)
Acquisitions (Net)00030K0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0000(72M)
Investing Cash Flow(14.94K)(84.19K)(21.39K)20.03K(72.92M)
Debt Repayment00000
Common Stock Issued10.7M4.16M28.71M5.4K5K
Common Stock Repurchased0000(177K)
Dividends Paid00000
Other Financing Activities25.03K0116.5K0323.16M
Financing Cash Flow10.72M4.16M28.82M5.4K322.98M
Effect of Forex Changes00000
Net Change in Cash(46.78M)(42.38M)(6.08M)(31.07M)178.53M
Free Cash Flow(57.5M)(46.54M)(34.9M)(31.11M)(72.45M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$149.9M
+ D&A$84.0K
+ Stock-Based Comp$13.3M
+ Deferred Tax$0
- Working Capital-$13.4M
+ Other Non-Cash$78.4M
= Operating Cash Flow-$71.5M
- Capex-$919.0K
= Free Cash Flow-$72.5M

Analysis

FY2025 free cash flow is -$72.5M. FCF conversion is 48.3% of net income. Operating cash flow was -$71.5M, with capex of -$919.0K. The largest bridge item is Other Non-Cash at $78.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingOct 27, 2026
8-KCurrent reportOct 15, 2026
4Statement of changes in beneficial ownershipSep 18, 2026

Does CBIO generate free cash flow?

Crescent Biopharma, Inc. (CBIO) generated -$72.45M of free cash flow in fiscal 2025.

How much operating cash flow does CBIO produce?

Operating cash flow was -$71.53M, before capital expenditures of $919,000.00.